TopoTarget ændrer sine resultatforventninger til regnskabsåret 2009 til et underskud før skat i størrelsesordenen DKK 120-130 mio. fra tidligere udmeldt DKK 140-160 mio.

Topotarget
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com


Copenhagen, Denmark - February 11, 2010 - TopoTarget A/S (NASDAQ OMX: TOPO.CO)
today announced a change in its pre-tax loss guidance for the 2009 year to a
range of DKK 120-130 million before any write-downs on research and development
projects that may occur. The previous guidance on pre-tax loss for the 2009
year was given in conjunction with the Company's June 2009 capital increase and
was for a range of DKK 140-160 million. The change is due to both differences
in the timing of some expenditure items plus savings resulting from improved
efficiencies. 



TopoTarget A/S

For further information, please contact:

Peter Buhl Jensen	Telephone	+45 39 17 94 99
CEO		Mobile	+45 21 60 89 22
	

Background information


About TopoTarget 
TopoTarget (OMX: TOPO) is an international biotech company headquartered in
Denmark, dedicated to finding ''Answers for Cancer'' and developing improved
cancer therapies. The company was founded and is run by clinical cancer
specialists and combines years of hands-on clinical experience with in-depth
understanding of the molecular mechanisms of cancer. 
TopoTarget has a broad clinical pipeline but is currently in collaboration with
Spectrum Pharmaceuticals Inc. focusing on the development of belinostat, which
has shown proof of concept as monotherapy in treating haematological
malignancies and positive results in solid tumours where it can be used in
combination with full doses of chemotherapy, and is in a pivotal trial in PTCL.
TopoTarget's expertise in translational research is utilizing its highly
predictive in vivo and in vitro cancer models. TopoTarget is directing its
efforts on key cancer targets including HDACi, NAD+, mTOR, FasLigand and
topoisomerase II inhibitors. The company's first marketed product
Savene®/Totect® was approved by EMEA in 2006 and the FDA in 2007 and is
marketed by TopoTarget's own sales force in Europe and the US. For more
information, please refer to www.topotarget.com. 

TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. TopoTarget cautions investors that
there can be no assurance that actual results or business conditions will not
differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
TopoTarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks;  uncertainty of additional funding; TopoTarget's history of
incurring losses and the uncertainty of achieving profitability; TopoTarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against TopoTarget's products, processes and
technologies; the ability to protect TopoTarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability expo-sure; We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.